Sapu Bioscience 扩大 OT-101 国际知识产权覆盖范围，强化中枢神经系统与神经病学领域的商业化途径

Core Insights - Sapu Bioscience announced advancements in the global intellectual property portfolio supporting its proprietary TGF-β antisense therapy platform, OT-101, enhancing its protection in neurology, oncology, and central nervous system drug delivery [1] Group 1: OT-101 Overview - OT-101 is a clinical-stage TGF-β antisense inhibitor that has previously undergone clinical trials for glioblastoma and pancreatic cancer, with a focus on developing it as a treatment platform for central nervous system capabilities [2][7] - The company has received patent approval in Australia for the use of OT-101 in treating Parkinson's disease, covering treatment methods, drug preparation methods, and central nervous system delivery routes including intrathecal and intracranial infusion [3] Group 2: Intellectual Property Developments - In China and Germany, the company has been granted utility model patents for a device for continuous intracranial infusion of fluid drug formulations, effective from April 1, 2025, in China and with protection until 2033 in Germany, providing device-level intellectual property protection for continuous intracranial infusion technology [4] - These intellectual property advancements create an integrated commercialization platform for OT-101, combining treatment use claims with authorized delivery device protections, thereby enhancing its strategic value in research, collaboration, and commercialization [5] Group 3: Management Commentary - CEO Vuong Trieu stated that the granting of these patents marks a critical turning point in the development of OT-101, establishing a comprehensive intellectual property fortress around the central nervous system strategy, making OT-101 a fully protected platform from molecular to delivery device, and ready for strategic collaborations and clinical trials [6] Group 4: Deciparticle™ Platform - The Deciparticle™ platform is a proprietary nanotechnology that encapsulates hydrophobic molecules into nanoparticles smaller than 20 nanometers for intravenous administration, enhancing systemic drug exposure levels and achieving precise delivery at clinical scale [8] Group 5: Company Background - Sapu Bioscience is a clinical-stage biotechnology company focused on advancing its proprietary platforms in oncology and neurology, including OT-101 and the Deciparticle™ nanodrug platform, and operates a cGMP manufacturing facility compliant with ISO-5 standards [9]